# Early is Good

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/early-is-good

- Industry: Healthcare
- Headquarters: Indianapolis, US
- Website: www.earlyisgood.com
- Total disclosed funding: $1.5M
- Latest round: Seed (Oct 14, 2022)
- Investors on record: 1

## About

Founded in 2019 by Thakshila Liyanage (CEO), and based in Indianapolis, US, Early is Good operates as a nanotechnology platform that uses a non-invasive diagnostic test to help individuals detect renal system diseases and cancer in an early stage. In October 2022, Early is Good, Inc. raised USD 4 million in seed funding from Social Capital.

The company enables the early and accurate detection of renal system diseases, such as bladder, kidney, and prostate cancers, by analyzing specific biomarkers found in urine that detect healthy versus oncogenic phenotypes. The test results are used to detect, treat, and manage renal cancer and other diseases in their early stages, thereby improving the patient's chances of survival.

The company intends to use the October 2022 funding to support its product’s clinical trials.

## Funding rounds

- Seed, Oct 14, 2022, $1.5M — Social Capital

## Investors

- Social Capital (https://capitalatlas.ai/funds/social-capital) — Seed